Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals develops and commercializes GI therapies, notably linaclotide (LINZESS/CONSTELLA) for IBS‑C and chronic constipation, while targeting rare diseases with IW‑3300 and Apraglutide. Strategic alliances with AbbVie, AstraZeneca, and Astellas drive growth.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 253
HQ: Boston

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
IRWD	Ironwood Pharmaceuticals Inc. Cap: 0.7B \| P/E: 22.6	EQUITY	NMS	USD	US46333X1081	Active	📈